CH Biotech Ser (08037) released its interim results for the six months ended June 30, 2024, with the group...
ZhongGuoShengWuKeJiFuWu (08037) released its interim results for the six months ended on June 30, 2024. The group achieved a turnover of HKD 32.449 million; the net loss attributable to owners of the company was HKD 79.917 million; and the loss per share was HKD 0.083.
Despite the intensified market competition in the medical laboratory testing services and health check services sector in the post-pandemic period, the group chose to upgrade its medical laboratories to improve efficiency and capability. At the beginning of 2024, its standard pathology laboratory collaborated with Abbott Laboratories to implement a customized virtual biochemistry immunosimulation GLPTrack, becoming the first private medical laboratory in Hong Kong to install such a system. This system effectively shortens the time for generating reports, increases testing throughput, processes samples in a closed system, frees up manpower, reduces human errors, and lays a solid foundation for future industry-compliant testing. The laboratory has initiated the qualification application process for the Hong Kong Laboratory Accreditation Program and aims to obtain accreditation by 2025, participating in government tenders to provide testing services to the Hospital Authority and the Department of Health in Hong Kong. In addition, the government has announced the establishment of the Food and Drug Administration (FDA) in Hong Kong to attract pharmaceutical companies to conduct clinical trials. The group has quickly collaborated with multiple partners to prepare for launching Contract Research Organization (CRO) services for local and overseas pharmaceutical companies.
